No Data
No Data
CRO Enterprise Yangguang Nuohuo achieved growth against the trend in the first half of the year, but the slowdown in pharmaceutical research and development has brought uncertainty. | Earnings conference
①In the current "cooling off" period in the CRO track, Yangguang Nuohuo achieved performance growth in the first half of the year. Chairman Li Qian said that 80% of the customers are traditional medium to large-sized domestic pharmaceutical companies with stable cash flow and product pipeline needs; ②The research and development targets of Yangguang Nuohuo are mainly generic drugs, supplemented by innovative drugs. With the implementation of policies such as drug consistency evaluation and quantity-based procurement, Yangguang Nuohuo faces the risk of declining performance.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Sunshine Kaidi (688621.SH): The net income in the first half of the year was 0.149 billion yuan, a 25.91% year-on-year increase.
Yangguang Nuohe (688621.SH) announced its semi-annual report for 2024, achieving a revenue of 0.563 billion yuan, a year-on-year growth of 22.08%; net income attributable to shareholders of listed companies was 0.149 billion yuan, a year-on-year growth of 25.91%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.143 billion yuan, a year-on-year growth of 24.49%; basic earnings per share was 1.33 yuan.
Sunshine Nuohe (688621.SH): multiple peptide projects for weight loss and blood sugar reduction have received multiple pharmaceutical and clinical research service orders.
On August 6, Gelon Hui reported that Sunshine Nuohe (688621.SH) has received multiple pharmaceutical and clinical research service orders for its weight loss and hypoglycemic polypeptide project. Currently, the company has accepted the commission from Brightgene Bio-Medical Technology Co. Ltd. for the under-research BGM0504 injection, which is mainly used for the indications of hypoglycemia and weight loss and has entered clinical phase III trials.
Sunshine Nova (688621.SH): Shengpu Pharmaceuticals has accumulated a purchase of 0.35% of the shares.
On July 24th, Gelunhui reported that Yangguang Nuohe (688621.SH) announced that from April 1st, 2024 to July 24th, Shengpu Pharmaceuticals had cumulatively purchased a total of 0.3972 million shares through centralized bidding, accounting for 0.35% of the company's total share capital. The purchase amount was 16 million yuan, and the purchase amount has reached 50% of the planned amount for purchasing company shares.
No Data
No Data